{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T18:14:26Z","timestamp":1784052866000,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To examine changes in patient-reported distress in female breast cancer (hormone-receptor-positive, stages 1\u20133) patients aged 55\u2009+\u2009taking adjuvant endocrine therapy (AET).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective cohort was constructed using the electronic health record (EHR) at a single Midwestern site from 2014 to 2019. Patients (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009390) were included if they had completed two or more distress thermometer (DT) assessments. The DT is scored from 0 to 10; four is the threshold for clinically concerning distress. Trajectories were assigned using group-based trajectory modeling analyses. Predictors of group membership were identified using a cross-validated lasso algorithm.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The best-fit model included four groups. Group 1 (22%) had no distress, Group 2 (29%) had low distress (average DT\u2009=\u20090.8) that remained low, Group 3 (33%) had medium\u2013low distress (2.7) that remained low, and Group 4 (16%) had high distress (6.2) that decreased but remained high (5) over time. Higher initial DT value was associated with a decreased odds of membership in Group 1 (OR\u2009=\u20090.88; 95% CI (0.80\u20130.95)) and increased in Group 4 (OR\u2009=\u20091.14; 95% CI (1.06\u20131.25)). Endorsement of sleep issues was associated with decreased odds of membership in Group 1 (OR\u2009=\u20090.59; 95% CI (0.40\u20130.87)) and increased odds of membership in Group 3 (OR\u2009=\u20091.53; 95% CI (1.11\u20132.26)).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The majority of post-menopausal women do not report distress while taking AET; however, one in six reports high distress that did not dissipate with time. This work adds to the understanding of distress in breast cancer survivors and supports the use of the DT in providing actionable information on distress and its causes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00520-026-10915-4","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T05:47:00Z","timestamp":1782366420000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient-reported distress and correlates while on adjuvant endocrine therapy following breast cancer treatment among post-menopausal women: a group-based trajectory model analysis"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5293-7781","authenticated-orcid":false,"given":"Kara L.","family":"Gavin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Tiegs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2906-3913","authenticated-orcid":false,"given":"Aaron N.","family":"Winn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaia","family":"Makris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0031-5988","authenticated-orcid":false,"given":"Joan M.","family":"Neuner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4427-3583","authenticated-orcid":false,"given":"Kathryn E.","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"issue":"4","key":"10915_CR1","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1200\/JCO.2007.11.5451","volume":"26","author":"AH Partridge","year":"2008","unstructured":"Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A (2008) Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 26(4):556\u2013562. https:\/\/doi.org\/10.1200\/JCO.2007.11.5451","journal-title":"J Clin Oncol"},{"issue":"4","key":"10915_CR2","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1200\/JCO.2003.07.071","volume":"21","author":"AH Partridge","year":"2003","unstructured":"Partridge AH, Wang PS, Winer EP, Avorn J (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21(4):602\u20136. https:\/\/doi.org\/10.1200\/JCO.2003.07.071","journal-title":"J Clin Oncol"},{"issue":"21","key":"10915_CR3","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.1200\/JCO.2008.19.2419","volume":"27","author":"G Kimmick","year":"2009","unstructured":"Kimmick G, Anderson R, Camacho F, Bhosle M, Hwang W, Balkrishnan R (2009) Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J Clin Oncol 27(21):3445\u201351. https:\/\/doi.org\/10.1200\/JCO.2008.19.2419","journal-title":"J Clin Oncol"},{"issue":"1\u20132","key":"10915_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000100444","volume":"71","author":"RT Chlebowski","year":"2006","unstructured":"Chlebowski RT, Geller ML (2006) Adherence to endocrine therapy for breast cancer. Oncology 71(1\u20132):1\u20139. https:\/\/doi.org\/10.1159\/000100444","journal-title":"Oncology"},{"issue":"2","key":"10915_CR5","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s10549-012-2114-5","volume":"134","author":"CC Murphy","year":"2012","unstructured":"Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134(2):459\u2013478. https:\/\/doi.org\/10.1007\/s10549-012-2114-5","journal-title":"Breast Cancer Res Treat"},{"key":"10915_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.breast.2022.01.012","volume":"62","author":"I Yussof","year":"2022","unstructured":"Yussof I, Mohd Tahir NA, Hatah E, Mohamed SN (2022) Factors influencing five-year adherence to adjuvant endocrine therapy in breast cancer patients: a systematic review. Breast 62:22\u201335. https:\/\/doi.org\/10.1016\/j.breast.2022.01.012","journal-title":"Breast"},{"issue":"1","key":"10915_CR7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jpainsymman.2023.10.001","volume":"67","author":"KE Post","year":"2024","unstructured":"Post KE, Ahmad Z, Jankauskaite G, Centracchio J, Oswald L, Horick N et al (2024) Managing symptom distress: key factors for patients on adjuvant endocrine therapy for breast cancer. J Pain Symptom Manage 67(1):88\u201397. https:\/\/doi.org\/10.1016\/j.jpainsymman.2023.10.001","journal-title":"J Pain Symptom Manage"},{"issue":"9324","key":"10915_CR8","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1016\/s0140-6736(02)09088-8","volume":"359","author":"M Baum","year":"2002","unstructured":"Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG et al (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359(9324):2131\u20132139. https:\/\/doi.org\/10.1016\/s0140-6736(02)09088-8","journal-title":"Lancet"},{"issue":"5","key":"10915_CR9","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1200\/JCO.2006.08.8617","volume":"25","author":"AS Coates","year":"2007","unstructured":"Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF et al (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25(5):486\u201392. https:\/\/doi.org\/10.1200\/JCO.2006.08.8617","journal-title":"J Clin Oncol"},{"issue":"9561","key":"10915_CR10","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S0140-6736(07)60200-1","volume":"369","author":"RC Coombes","year":"2007","unstructured":"Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE et al (2007) Survival and safety of exemestane versus tamoxifen after 2-3 years\u2019 tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369(9561):559\u201370. https:\/\/doi.org\/10.1016\/S0140-6736(07)60200-1","journal-title":"Lancet"},{"issue":"2","key":"10915_CR11","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.3390\/curroncol30020112","volume":"30","author":"R Rosso","year":"2023","unstructured":"Rosso R, D\u2019Alonzo M, Bounous VE, Actis S, Cipullo I, Salerno E et al (2023) Adherence to adjuvant endocrine therapy in breast cancer patients. Curr Oncol 30(2):1461\u201372. https:\/\/doi.org\/10.3390\/curroncol30020112","journal-title":"Curr Oncol"},{"issue":"12","key":"10915_CR12","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1002\/acr.21756","volume":"64","author":"O Singer","year":"2012","unstructured":"Singer O, Cigler T, Moore AB, Levine AB, Hentel K, Belfi L et al (2012) Defining the aromatase inhibitor musculoskeletal syndrome: a prospective study. Arthritis Care Res (Hoboken) 64(12):1910\u20138. https:\/\/doi.org\/10.1002\/acr.21756","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10915_CR13","doi-asserted-by":"publisher","DOI":"10.1177\/11782234221145440","volume":"17","author":"A Johnsson","year":"2023","unstructured":"Johnsson A, Fugl-Meyer K, Bordas P, \u00c5hman J, Von Wachenfeldt A (2023) Side effects and its management in adjuvant endocrine therapy for breast cancer: a matter of communication and counseling. Breast Cancer Basic Clin Res 17:11782234221145440. https:\/\/doi.org\/10.1177\/11782234221145440","journal-title":"Breast Cancer Basic Clin Res"},{"key":"10915_CR14","unstructured":"\u00a0National Comprehensive Cancer Network (2023) NCCN clinical practice guidelines in oncology: distress management, version 1.2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/distress.pdf. Accessed 12 Jan 2024"},{"issue":"2","key":"10915_CR15","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s10549-022-06805-y","volume":"197","author":"TE Lacourt","year":"2023","unstructured":"Lacourt TE, Koncz Z, Tullos EA, Tripathy D (2023) A detailed description of the distress trajectory from pre- to post-treatment in breast cancer patients receiving neoadjuvant chemotherapy. Breast Cancer Res Treat 197(2):299\u2013305. https:\/\/doi.org\/10.1007\/s10549-022-06805-y","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"10915_CR16","doi-asserted-by":"publisher","first-page":"903","DOI":"10.6004\/jnccn.2017.0120","volume":"15","author":"B Zebrack","year":"2017","unstructured":"Zebrack B, Kayser K, Bybee D, Padgett L, Sundstrom L, Jobin C et al (2017) A practice-based evaluation of distress screening protocol adherence and medical service utilization. J Natl Compr Canc Netw 15(7):903\u201312. https:\/\/doi.org\/10.6004\/jnccn.2017.0120","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10915_CR17","first-page":"175","volume":"10","author":"KK Ownby","year":"2019","unstructured":"Ownby KK (2019) Use of the distress thermometer in clinical practice. J Adv Pract Oncol 10(2):175\u2013179","journal-title":"J Adv Pract Oncol"},{"issue":"3","key":"10915_CR18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1200\/JOP.2015.003954","volume":"11","author":"AC Chiang","year":"2015","unstructured":"Chiang AC, Buia Amport S, Corjulo D, Harvey KL, McCorkle R (2015) Incorporating patient-reported outcomes to improve emotional distress screening and assessment in an ambulatory oncology clinic. J Oncol Pract 11(3):219\u2013222. https:\/\/doi.org\/10.1200\/JOP.2015.003954","journal-title":"J Oncol Pract"},{"issue":"33","key":"10915_CR19","doi-asserted-by":"publisher","first-page":"4884","DOI":"10.1200\/JCO.2009.27.3698","volume":"28","author":"LE Carlson","year":"2010","unstructured":"Carlson LE, Groff SL, Maciejewski O, Bultz BD (2010) Screening for distress in lung and breast cancer outpatients: a randomized controlled trial. J Clin Oncol 28(33):4884\u201391. https:\/\/doi.org\/10.1200\/JCO.2009.27.3698","journal-title":"J Clin Oncol"},{"issue":"3","key":"10915_CR20","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1136\/bmjspcare-2021-002960","volume":"12","author":"H Sun","year":"2022","unstructured":"Sun H, Lv H, Zeng H, Niu L, Yan M (2022) Distress thermometer in breast cancer: systematic review and meta-analysis. BMJ Support Palliat Care 12(3):245\u201352. https:\/\/doi.org\/10.1136\/bmjspcare-2021-002960","journal-title":"BMJ Support Palliat Care"},{"issue":"3","key":"10915_CR21","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10549-024-07513-5","volume":"209","author":"JM Neuner","year":"2025","unstructured":"Neuner JM, Stolley M, Kamaraju S, Tiegs J, Sparapani R, Makris V et al (2025) The association of distress and depression screening measures and other electronic health record information with adjuvant endocrine therapy persistence. Breast Cancer Res Treat 209(3):541\u201352. https:\/\/doi.org\/10.1007\/s10549-024-07513-5","journal-title":"Breast Cancer Res Treat"},{"key":"10915_CR22","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1097\/01.MLR.0000093487.78664.3C","volume":"41","author":"K Kroenke","year":"2003","unstructured":"Kroenke K, Spitzer RL, Williams JB (2003) The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care 41:1284\u20131292","journal-title":"Med Care"},{"issue":"26","key":"10915_CR23","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1056\/NEJMp1802313","volume":"378","author":"AJH Kind","year":"2018","unstructured":"Kind AJH, Buckingham WR (2018) Making neighborhood-disadvantage metrics accessible \u2014 the neighborhood atlas. N Engl J Med 378(26):2456\u20138. https:\/\/doi.org\/10.1056\/NEJMp1802313","journal-title":"N Engl J Med"},{"issue":"7","key":"10915_CR24","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1177\/0962280216673085","volume":"27","author":"DS Nagin","year":"2018","unstructured":"Nagin DS, Jones BL, Passos VL, Tremblay RE (2018) Group-based multi-trajectory modeling. Stat Methods Med Res 27(7):2015\u20132023. https:\/\/doi.org\/10.1177\/0962280216673085","journal-title":"Stat Methods Med Res"},{"issue":"7867","key":"10915_CR25","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41586-021-03602-3","volume":"595","author":"L Magrini","year":"2021","unstructured":"Magrini L, Rosenzweig P, Bach C, Deutschmann-Olek A, Hofer SG, Hong S et al (2021) Real-time optimal quantum control of mechanical motion at room temperature. Nature 595(7867):373\u20137. https:\/\/doi.org\/10.1038\/s41586-021-03602-3","journal-title":"Nature"},{"issue":"1","key":"10915_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v033.i01","volume":"33","author":"JH Friedman","year":"2010","unstructured":"Friedman JH, Ht a (2010) Regularization paths for generalized linear models via coordinate descent. J Stat Softw 33(1):1\u201322. https:\/\/doi.org\/10.18637\/jss.v033.i01","journal-title":"J Stat Softw"},{"key":"10915_CR27","doi-asserted-by":"publisher","DOI":"10.1201\/b18401","volume-title":"Statistical learning with sparsity: the lasso and generalizations","author":"T Hastie","year":"2015","unstructured":"Hastie T, Tibshirani R, Wainwright M (2015) Statistical learning with sparsity: the lasso and generalizations. Chapman & Hall\/CRC"},{"issue":"2","key":"10915_CR28","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1159\/000350780","volume":"8","author":"S Kilickap","year":"2013","unstructured":"Kilickap S, Hayran M, Cakir B, Cilingiroglu N, Erman M, Buyukdamgaci G et al (2013) Effect of endocrine therapy on quality of life and cognitive functions in patients with breast cancer. Breast Care 8(2):128\u201332. https:\/\/doi.org\/10.1159\/000350780","journal-title":"Breast Care"},{"issue":"5","key":"10915_CR29","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.breast.2014.06.002","volume":"23","author":"JM Neuner","year":"2014","unstructured":"Neuner JM, Zokoe N, McGinley EL, Pezzin LE, Yen TW, Schapira MM et al (2014) Quality of life among a population-based cohort of older patients with breast cancer. The Breast 23(5):609\u201316. https:\/\/doi.org\/10.1016\/j.breast.2014.06.002","journal-title":"The Breast"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10915-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-10915-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10915-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T18:03:00Z","timestamp":1784052180000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-10915-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10915"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-10915-4","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"11 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Study procedures were reviewed and approved by the Medical College of Wisconsin Institutional Review Board and conducted in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"688"}}